Topical pimecrolimus (Elidel), a nonsteroidal anti-inflammatory medication, can control the symptoms of atopic dermatitis in infants aged 3 to 23 months without the risk of skin atrophy or systemic adverse effects, according to the results of a double-blind controlled trial reported in the August issue of the Journal of Allergy and Clinical Immunology.
“These results indicate that Elidel may offer significant therapeutic advantages over other treatment strategies in the long-term management of chronic eczema in infants and young children,” Lawrence Eichenfeld, MD, says in a news release. He is a clinical professor of pediatrics and medicine at University of California at San Diego and did not author the study. “A steroid-free therapy like Elidel provides a new alternative for this difficult-to-treat young patient group.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!